GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (OTCPK:INRLF) » Definitions » Cyclically Adjusted Price-to-FCF

INRLF (Valneva SE) Cyclically Adjusted Price-to-FCF : (As of May. 29, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Valneva SE Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Valneva SE Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Valneva SE's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Cyclically Adjusted Price-to-FCF Chart

Valneva SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 341.62 2,428.61 - - -

Valneva SE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Valneva SE's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Valneva SE's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Valneva SE's Cyclically Adjusted Price-to-FCF falls into.


;
;

Valneva SE Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Valneva SE's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Valneva SE's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.068/120.3800*120.3800
=-0.068

Current CPI (Mar. 2025) = 120.3800.

Valneva SE Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.025 100.440 -0.030
201509 -0.083 99.950 -0.100
201512 -0.068 100.040 -0.082
201603 -0.110 100.020 -0.132
201606 0.149 100.630 0.178
201609 0.048 100.340 0.058
201612 -0.048 100.650 -0.057
201703 0.142 101.170 0.169
201706 0.037 101.320 0.044
201709 0.017 101.330 0.020
201712 -0.100 101.850 -0.118
201803 0.067 102.750 0.078
201806 0.124 103.370 0.144
201809 -0.041 103.560 -0.048
201812 0.043 103.470 0.050
201903 0.052 103.890 0.060
201906 0.089 104.580 0.102
201909 -0.165 104.500 -0.190
201912 -0.020 104.980 -0.023
202003 0.029 104.590 0.033
202006 1.349 104.790 1.550
202009 -0.561 104.550 -0.646
202012 0.645 104.960 0.740
202103 0.396 105.750 0.451
202106 0.168 106.340 0.190
202109 -0.879 106.810 -0.991
202112 0.201 107.850 0.224
202203 -0.369 110.490 -0.402
202206 -0.778 112.550 -0.832
202209 -0.895 112.740 -0.956
202212 -0.478 114.160 -0.504
202303 -0.216 116.790 -0.223
202306 -0.342 117.650 -0.350
202309 -0.573 118.260 -0.583
202312 -0.564 118.390 -0.573
202403 -0.249 119.470 -0.251
202406 -0.289 120.200 -0.289
202409 -0.191 119.560 -0.192
202412 0.081 119.950 0.081
202503 -0.068 120.380 -0.068

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Valneva SE  (OTCPK:INRLF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Valneva SE Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Valneva SE's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE Business Description

Industry
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.